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Ambulatory chemotherapy allows the delivery of short and extended chemotherapy 
infusions through a portable pump from the comfort of patients’ homes. It is essential to 
offer it for suitable candidates to ensure both their safety and the success of the treatment 
session. This requires a delicate balance between clinical assessment and patient 
acceptance. 
The two main components of this treatment modality are the pump and the access device. 
There are several pump designs and mechanisms on the market, with the latest being the 
portable disposable elastomeric one. 
Clinicians along with a multidisciplinary medical team often decide upon the type of access 
device; patients are also involved whenever shared decision making is practiced.  
Despite some reports of pump programming errors or malfunctions, research is underway to 
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CDC: the Centers for Disease Control 
CRBSI: Catheter related blood stream infections 
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1. Background and definitions  
Historically, the provision of chemotherapy infusions was solely delivered on an inpatient 
basis on oncology wards. For the past decades, the worldwide growing cancer incidence 
increased the strain on hospital resources as well as the patient travel and waiting times, 
thus affecting their treatment experience. 
Breakthrough in oncology clinical practice gradually shifted chemotherapy provision to the 
outpatient settings and later closer to home thus optimising hospital capacity and improving 
patient satisfaction. The choice of the setting and route of administration of the treatment 
depend on the prescribed chemotherapy protocol and medical status of the patient (1) 
(table 1). 
These treatment patterns have had an erratic uptake between and within countries. 
Whereas treatment at the one-day chemotherapy unit is well established in most 
continents, ambulatory and home chemotherapy are more seen in developed and Western 
countries, such as Canada and the UK (1,2). 
Ambulatory chemotherapy (AC) allows the delivery of short (5-7 hours) and extended (1- 5 
days) chemotherapy infusions through a portable pump from the comfort of patients’ 
homes. 
The connected infusion pump might need to be replaced during the course of treatment 
depending on its capacity and the length of the continuous infusion. This is carried out by a 
visiting home nurse, by the patients or carers at home, or during another hospital visit. 
There are different types of portable infusion pumps on the market with variable 
specifications. These could be connected to the patients either peripherally or through a 
central access device. 
 The purpose of this review is to present ambulatory chemotherapy delivery and share 
relevant practice experiences. This review will cover the two main components of 
ambulatory chemotherapy, the pump and the central access devices; the different types, 
their safety, and experience to date. The review will also shed light on the necessary 
assessment for patients deemed suitable candidates for AC, and the impact of the latter on 
healthcare delivery. 
2.0 Patient assessment for Ambulatory Chemotherapy  
It is essential to offer AC for suitable candidates to ensure both their safety and the success 
of the treatment session. This requires a delicate balance between clinical assessment and 





Clinical assessment is comprised of five checkpoints, the first of which is a stable clinical 
status allowing safe hospital discharge. Performance scales such as the Eastern Cooperative 
Oncology Group (ECOG) performance scale or Karnofsky performance scale could be used 
for this purpose.  
The second checkpoint relates to the suitability of the chemotherapy agent for ambulatory 
delivery. Published pilot studies on Ifosfamide, Trabectidin, and Fluorouracil confirmed that 
these could be safely administered on an ambulatory basis without the need for direct 
continuous medical monitoring (3–5). Newton et al. lists further chemotherapy regimens 
administered as case studies at University College London Hospitals NHS Foundation Trust (1). 
The third checkpoint is having a means of communication such as a mobile phone to 
facilitate access to support in case of emergency.  
Ability for self-care and management of side effects comprises the fourth checkpoint. It 
entails a clean home environment confirmed by the patient with cooperative family 
member(s) willing to accompany patients during the treatment sessions and learn support 
measures. 
Proximity to a hospital is the fifth checkpoint ensuring access to support in case of 
emergency. A 30-60-minute travel time is acceptable, otherwise patients are invited to stay 
in a nearby hotel.  
Patients’ acceptance for AC is portrayed in their consent to receive AC especially that they 
will be actively involved in the treatment. Patients’ choice in only implied in cultures and 
countries where shared decision making is practiced. A qualitative research conducted with 
cancer patients in Lebanon, a small Mediterranean country, assessed the diffusion of AC. 
Results showed that lack of patient empowerment led to oncologists taking all treatment 
related decisions on their behalf (6). 
Recently, telehealth platforms extended care management outside hospital wards.  Remote 
monitoring  of AC patients is undergoing extensive research in order to optimize patient 
experience and safety (1,7–9). This telemonitoring opportunity provides virtual support and 
a sense of security to patients as demonstrated in several studies (10,11). 
As such, when adequately assessed for AC, treated patients achieve improved health 
outcomes. 
3.0. Infusion pumps  
Infusion pumps are mainly classified according to the below attributes: 
- Operation mechanism; mechanical, electronic 
- Pumping mechanism design; elastomeric, spring, vacuum 
- Delivered product; chemotherapy, insulin, analgesics, etc. 





- Safety features; alarm, software 
As such, the choice of pump lies in the detailed assessment of its use and context; a pump 
connected to a patient planned for discharge should most importantly be lightweight and 
free of programming errors, whereas a high risk medication should be delivered through a 
pump offering a high level of accuracy (12).  
Additional considerations include the patients’ ability to handle the connected pump, its 
availability at the hospital where the patient is receiving treatment, its cost, and insurance 
coverage (13). 
Portable pumps have been introduced to alleviate pressure from hospital premises and 
support ambulatory treatment (7) 6. In the late 1970, a preliminary disposable portable 
infuser was used to deliver bleomycin and 5FU in the ambulatory setting. Despite the 
technical complications, mainly related to inconsistencies in the flow rate, the absence of 
severe complications was a promising finding calling for technical enhancements to the 
infuser (14).  
Since then, advancements in pump technology made ambulatory chemotherapy more 
reliable and safer to use. Portable electronic and mechanical pumps were designed each 
offering different advantages.  
There are two main types of portable infusion pumps; the battery operated and the 
disposable mechanical ones. 
3.1. Battery operated smart pumps  
Also known as peristaltic pumps, these are programmable battery-operated infusion pumps 
with sizes of around 4 cm X 10 cm X 14 cm and weighing around 500g. An attached 
medication cassette that holds the infusion bag is situated at the bottom of the screen and 
input pad.   
In addition to being safe and simple to use, these pumps can provide assessment graphs and 
reports, and are equipped with alarms to notify errors such as low battery power, occlusion, 
faults, and air in line. These pumps also provide a high flow rate accuracy (±2.5-6%), and 
offer no restrictions on the volume and rate of infusion (12,13,15–17).  
The name “smart pump” was adapted owing to two main software components; dose error 
reduction systems (DERS) and drug libraries. Drug libraries are customized according to the 
practice at each hospital and ward to hold predefined parameters of the drug’s dose limits, 
strengths and other specifications. As such, the pump supports the user in setting up the 





troubleshoots such as occlusion. Depending on the severity of the encounter these are 
referred to as soft or hard limits, with the latter requiring confirmation by a clinician to 
override the alert (17,18).  
A systematic review published in 2014 concluded that using smart pumps to infuse 
medications could decrease programming errors but not eliminate them. One of the 
retrieved studies found that pumps detected 79% of the encountered errors, and two other 
studies evaluating the severity of these errors classified them as “serious”, “catastrophic” or 
“potentially dangerous” (18). 
Ohashi et al. further describes the advantages of these pumps in supporting the nurses with 
dose calculations and adjustments, as well as connecting to the barcoding systems. For 
optimal use, this pump should be coupled to continuous quality improvement processes 
entailing the use, review and continuous update of the drug library (18). 
On the other hand, these pumps are associated with high risk of programming errors during 
set up, and patients often complain of the noisy alarm. Considering their weight and size, 
these are mostly used in-hospital as they have limited portability (13). 
In light of the current Covid-19 pandemic, the U.S. Food and Drug Administration (FDA) 
issued a report authorizing the use of infusion pumps and their accessories to treat Covid-19 
infected patients. The FDA also required that manufacturers of pumps provide guidance on 
the cleaning of these reusable devices, most importantly, to recommend cleaning material 
readily available to patients for use at home (19). Consequently, thorough and adequate 
cleaning of any reusable pump should be considered and thus requiring additional cost and 
time. 
Patients are advised not to shower/bath while a battery operated pump is connected; 
alternatively, a sponge bath is recommended (20). 
3.2. Disposable mechanical pumps  
These pumps use non-electric power to exert pressure on the fluid contained in the reservoir 
causing it to elute through narrow tubing into the patient’s body. There are three types of 
disposable mechanical pumps; positive pressure, negative pressure, and elastomeric (table 
2). Each type of pump has a certain driving force, but all are regulated by a flow restrictor 
which is a small part either taped to the patient’s skin or left to sense the room temperature. 
The pump is calibrated to infuse at a certain flow rate considering the temperature sensed 





Disposable pumps have many advantages including their light weight, small size, simplicity of 
use, independence from an external power supply, elimination of programming errors, 
disposability and low cost.  
The rate of infusion and thus accuracy and duration of therapy are affected by temperature, 
atmospheric pressure, and fluid viscosity 
Fluid viscosity, unlike temperature, is inversely proportional to flow rate, yet proportional to 
each other (22). For that, these pumps are often calibrated with 0.9% sodium chloride or 5% 
dextrose; the two commonly used solvents to achieve the flow rate stated on the pump. 
Other environmental conditions affect the performance of the pump, for example 
atmospheric pressure was found to be positively correlated with the flow rate (23).  
Partial filling of the pumps has been found to increase the flow rate, whereas storing 
elastomeric pumps at low temperatures hardened the elastomer thus decreasing the flow 
rate. It is therefore recommended to allow the refrigerated pumps to return to room 
temperature before connecting it to the patient. 
The disadvantages of disposable pumps are thus mainly related to inconsistencies in flow 
rate and accuracy (21).  
Patients with a connected portable infusion pump are advised to keep the pump at room 
temperature, not to submerge it in water while showering, and to keep it at the level of the 
abdomen when sleeping. Alternatively, patients are advised to place the pump under the 
pillow during sleep, and to cover it with a plastic bag and hang it outside the tub while 
showering. Patients are also encouraged to frequently monitor the progress of the infusion 
and to report any delay or faster than expected emptying of the pump. It is advisable to 
provide patients with a leaflet on the precautions of use and emergency numbers to contact 
in case of anything unusual (24–26).  
4.0 Safety of infusion pumps   
Considering that hazardous solutions are infused through these pumps, malfunctions could 
have deleterious effects on patient safety. Despite the established safety of AC, several 
incidents of missed, over- or under-infusions have been reported due to user error or to 
deficiencies in the design, engineering, or components of the pump in turn leading to user 
error.  
Between 2005 and 2009, the FDA received 56,000 reports of adverse events involving 
serious injuries and death resulting from mechanical, software, or programming errors 
related to the pumps (27). The most commonly reported incidents were due to defects in 





Reported incidents have been divided to six categories; (1) software problems, (2) alarm 
errors, (3) inadequate user interface design, (4) broken components, (5) battery failures, (6) 
electrical malfunctions.  
Problems in the software could lead to either an inoperable pump in the absence of a 
recognisable cause, or a misinterpretation of the input. As such, a 10mL/hour rate could be 
registered by the device as 100mL/hour.  
There is potential to encounter false positive or false negative alarms; for example, the 
device might fail to signal an occlusion in the tube or generate an alarm where there is no 
troubleshooting.  
User interface refers to the way a computer and a user interact (28) and when inadequate, 
such a design could lead to error. Discrepancies in the units, especially in the absence of 
system checks could lead to inadequate dosage or rate entry.  
There are reports of erroneous flow rates, sparks, charring and shock when using a broken 
or damaged pump or from power failures, especially when poor maintenance is devoted to 
these devices (29).  
Consequently, the FDA published a white paper in 2010 entitled “Infusion pump 
Improvement Initiative” requesting enhancements on the level of the manufacturing 
process, the design of the device, and spreading awareness amongst users in order to 
promote safety (30). 
Notwithstanding the various safety alerts and vigilant risk assessment and validation 
processes fostered, incidents of malfunctions and toxicities were still encountered. These 
are mainly traced back to “human errors” in calculations and pump set up or choice of the 
pump.  
In 2007, the Institute for Safe Medication Practices (ISMP) published a newsletter discussing 
the factors that led to the death of a 43-year-old Canadian patient who received high-dose 
fluorouracil via an ambulatory infusion pump. The programable pump, lacking a smart 
system to detect errors, was set to deliver the infusion over 4 hours instead of 4 days. 
Although the patient reported back to the clinic soon after the infusion had ended, no 
specific management of the overdose was undertaken which led to their death. 
Multifactorial events had led to this; there was an error in the calculations of the first nurse 
and an inadequate double-checking process by the second nurse. 
Additionally, the design of the pharmacy label was misleading as it states the rate in mL/24 
hour first then in mL/hour. 
Moreover, the nurses have a complex workload entailing several back to back high-risk tasks 





Further investigations revealed that an inexperienced nurse had programmed the pump. 
Finally, the lack of insight on the adequate management of chemotherapy overdose led to 
irreversible harm brought upon the patient by the pancytopenia, hemodynamic collapse, 
and multiorgan failure (31–33).  
In another article for the ISMP, three accidental overdoses of fluorouracil in 2015 were 
described. 
The first report describes how an error in programming a smart pump led to infusing a 2-day 
treatment over 2 hours. Despite the severe adverse events experienced, adequate 
management resulted in the patient’s complete recovery. 
Another incident was reported whereby a 4-day infusion of fluorouracil was administered in 
less than an hour. This error was traced back to the technician confusing the yellow labels of 
the 2ml/hour elastomeric infusion pump (EIP) and the 250ml/hour pump. A different nurse 
noticed the empty pump and corrective measures were started with the antidote uridine 
triacetate. 
The third report described a 5-fold fluorouracil overdose in a patient as a result of 
miscalculation by the pharmacist after the double-checking process was overlooked. The 
error was detected on the day of disconnecting the EIP and the patient was adequately 
managed (31).  
In 2010, the NHS published the “Design for patient safety: A guide to the design of electronic 
infusion devices” which addressed possible encounters and limitations with the 
programmable pumps and provided recommendations to manufactures and users. These 
recommendations aim at enhancing the design, functionality, and use of the pumps resulting 
in a better patient experience (34).  
In 2017, recommendations to prevent errors from the use of EIP induced by the staff or 
patients were delineated by both the ISMP and the South Australian Government. 
First, the enforcement of clear prescribing information and maintenance of skilled 
healthcare professionals involved in the delivery of toxic therapeutic regimens. These should 
be adequately informed of the components of the pump, the connection and disconnection 
process, storage conditions, and patient education. 
Second, it is highly recommended to use pumps that reduce the chances of errors through 
alerts and flow rate limits thus assisting in the verification of the correct infusion details. 
Third, using a single type of ambulatory pump within the organisation and providing 
education on the connection process further reduces the rates of error and keeps the staff 
familiar with the device. 
Fourth, checklists and double verification by a healthcare practitioner, patient or family 





Fifth, careful choice of patients for AC able to manage the pump in line with the provided 
instructions, and educating them about their treatment, dose, and duration of the infusion 
as well as the reporting of unusual side effects should be practiced. 
Finally, clear and standardized labels on the final preparation from the pharmacy 
department must be adopted (31).  
5.0 Central Access Device 
Appropriate vascular access and device selection for cancer patients should be assessed by 
the treating oncologist. The literature lacks strict guidance in this perspective as a variety of 
factors define the most appropriate access route including amongst others; patient status 
(age, comorbidities), the frequency and duration of treatment, the type of chemotherapy 
prescribed, patient preference and engagement in self-care, cost, and reimbursement 
schemes. The practice, therefore, varies between using peripherally and centrally inserted 
catheters (35–37). 
A recent survey conducted with Canadian oncologists and oncology nurses specialized in 
breast cancer assessed their access practices as well as their perceptions of risks and 
complications. Results showed that physicians are the main decision makers in this 
perspective and take into consideration prior IV access and feedback from the nursing team. 
The observed trend was that vesicant drugs were preferably infused via CAD, however, 
nurses recommended the use of CAD in all cases as they believed it is correlated with 
enhanced patient quality of life and conserved their veins. Despite the recognized 
complications related to both access routes and the lack of best practice guidance, CAD 
remains the preferred access route for oncologists (38). 
5.1 Rational for using Central Access Devices 
In addition to saving patients the anxiety and pain from repetitive venipuncture and 
cannulation, central access devices (CAD) serve as a long-term access to oncology patients 
requiring frequent and prolonged infusions. As these patients often require treatment over 
months to years, repetitive peripheral access, routinely replaced every 3-4 days, might 
reduce vein patency over the treatment duration (39).  
Moreover, vesicant and irritant chemotherapy drugs have the potential to cause injection 
site reaction and resulting serious extravasation. They require rapid dilution when injected 
which is achieved by infusion through central veins (39,40). On the other hand, the infusion 
flow and rate necessary to avoid extravasation increases the fragility of small peripheral 





Prevention of extravasation trough use of CAD has been warranted; for example, it is always 
recommended to infuse Trabectidin through a CAD (42,43). 
Published guidelines from the European Society of Medical Oncology (ESMO) and the 
American Society of Clinical Oncology (ASCO), recommend a Central Venous Access for 
oncology patients;  
“Long-term central venous access devices are essential in the management of oncology 
patients, as they minimise the discomfort of frequent venepuncture and cannulation” (36).  
“The management of the patient with cancer demands stable venous access that is used for a 
wide range of indications” (44).  
In what concerns AC, and since its main objective is for cancer patients to regain normalcy, 
patients connecting the pump will be actively ambulating and their movements, including 
those of their hands, unrestricted. In this perspective, CAD is more fit for use than 
peripherally inserted catheters to ensure habitual activity and avoid dislodgement. As such, 
clinical practice of renowned cancer centres recommend CAD for home infusion (45–48). 
The use of CAD also allows patients connecting a portable infusion pump to disconnect it at 
home thus avoiding a return trip to the hospital. For example, the Dana-Farber Cancer 
Institute and the Johns Hopkins Kimmel Cancer Center provide detailed online instructions 
to support patients in this task (49,50). 
This is essential at current times of Covid-19 pandemic when renowned institutions have 
issued guidelines and statements to decrease its impact on patients’ cancer care continuum. 
Home treatment coupled to telehealth have been put forward as an acceptable solution to 
safeguard patient safety while providing timely treatment sessions(51). 
 
5.2 Complications of Central Access Devices 
The use of CAD is associated with immediate and late complications, both of which should 
be prevented and well managed by a multidisciplinary specialized team. Preferably, this 
team would be comprised of medical oncologists/hematologists, registered nurses, 
interventional radiologists, surgeons and infectious disease specialists (36,52). Pharmacists 
are also an important pillar of this team as they are strategically positioned to offer support 
to patients. Community pharmacists are within reach to the public at the front end of 
healthcare services, whereas clinical pharmacists on hospital wards are proactively involved 
in discharge counselling to mitigate medication error (53). Pharmacists can provide 





related myths and misconceptions. Additionally, pharmacists can signpost patients to Non-
Governmental Organisations (NGO’s) for support and social reinforcement. 
The insertion technique is responsible for the immediate complications during catheter 
placement which can rapidly escalate to critical conditions (table 3). Ultrasound guidance 
has shown to drastically reduce the incidence of immediate complications (36,44,52). 
On the other hand, it could take weeks to years for the onset of delayed complications; 
related morbidity and mortality is greatly reduced with early recognition (table 3). Device 
dysfunction is often treated with fibrinolytics or catheter removal (44,52). 
CVC related infections have a high incidence in cancer patients and are classified as either local 
(at insertion site) or systemic (blood stream infection), thus called catheter related blood 
stream infections (CRBSI). Upon clinical manifestations of an infection, cultures are taken, and 
antibiotic therapy is started. CVC removal is indicated when infections result in sepsis, 
endocarditis, and port abscess, as well as when patients do not respond to 48-72 hours of 
antibiotic. Cultures positive for Staphylococcus aureus, fungi or mycobacteria also warrant CVC 
removal. Studies reported lower infections rates with port-a-caths compared to tunnelled 
catheters and peripherally inserted central catheters (PICC) lines (36). Coagulase-negative 
staphylococci, Staphylococcus aureus and Candida spp are the main cause of CRBSI. 
 
5.3 Types of Central Access Devices  
There are three mains types of CADs classified according to the way they are connected to 
the vessel (tunnelled, non-tunnelled, implanted), their insertion point (subclavian, jugular, 
etc.), and finally their characteristics (infused with antibiotic, antiseptics or other solutions) 
(table 4). 
5.4 Care for Central Access Devices  
Whenever the CAD is not in use, usually between treatment sessions, an antibiotic lock 
therapy is recommended to prevent infection of the biofilm. A highly concentrated antibiotic 
is combined with an anticoagulant and injected into the catheter to remain indwelling until it 
is accessed (36).  
Infections, thrombosis, and occlusion are possible complications of the CAD, however, the 
current treatment guidelines offer detailed regimens for the prevention and treatment of 
these events (36,37,44,54).  
In their recently updated guidelines, the Centers for Disease Control (CDC) listed 20 items for 





It is essential to designate trained healthcare personnel for managing patients with CAD as 
well as perform periodic assessment of knowledge. 
The guidelines also recommend careful selection of catheter type and insertion site based on 
the intended purpose, treatment duration, and patient medical history. 
Aseptic technique and adequate protective equipment were also described for performing 
catheter insertion and care. This also extends for skin preparation, catheter site dressing 
regimen as described with chlorhexidine and sterile gauze. 
The guidelines clearly advise to “Use a chlorhexidine/silver sulfadiazine or minocycline/rifampin -
impregnated CVC in patients whose catheter is expected to remain in place >5 days”. 
Systemic antibiotic prophylaxis is, however, not recommended before or during CAD 
insertion. Specific topical antibiotics and antiseptics are recommended for patients 
undergoing haemodialysis only.  
The CDC advises against the routine replacement of CVC and PICC lines, even in the presence 
of fever. The replacement of administration sets should be done every 96 hours to 7 days 
(54). 
Patients should be advised not to submerge the catheter in water and showering should only 
be permitted if the catheter and its entry point is protected with an impermeable cover. 
Patients are also counselled to report any discomfort or unusual observation, and to use a 
2% chlorhexidine solution for daily skin wash (54). Patients should also be educated on 
infection signs so to report them the earliest. 
6.0 Impact of Ambulatory Chemotherapy  
A robust national healthcare infrastructure is essential to foster a safe and well-established 
practice of AC. A multidisciplinary team of healthcare professionals is key to ensure a 
seamless experience for patients opting to receive AC. This is essential especially that AC 
cannot and is not planned to replace other treatment modalities. 
However, at times of the current Covid-19 pandemic, healthcare is shifting delivery of 
treatments to the home setting. This is especially valuable for cancer patients considering 
their immunosuppression, and for hospital resources as it optimizes use of hospital beds. A 
recent publication of the ASCO Post describes a successful implementation of a 
chemotherapy home delivery program; careful assessment is done for suitable patients, 
protocols, and home environments (55). As such, AC is a practical alternative to support in 
delivering chemotherapy agents with long enough stability and requiring minimal support at 





AC has the potential to positively impact the patient’s quality of life and alleviate pressure 
from the carers and the treating hospital. AC has been renowned for giving back the patients 
a sense of normality and control over their symptoms and treatment (56–58).  
In 2002, a prospective pilot single centre study in the UK assessed the feasibility of 
administering the deGramont regimen on an ambulatory basis using EIP compared to 
inpatient treatment. The study also aimed at capturing patient acceptability for this 
treatment modality, and its effect on their quality of life (59).   
The deGramont regimen, often delayed for logistic reasons, involves administering a 2-hour 
folinic acid, a 30-minute bolus 5FU infusion, and a 22-hour 5FU infusion intermittently over 2 
days. Twenty-six patients in total were recruited equally distributed between the outpatient 
and inpatient treatment groups.  
The outpatient treatment delivered a 48-hour 5FU infusion through a CAD for suitable 
patients, while the inpatient treatment delivered it through a peripheral line at the hospital. 
Patients received adequate counselling on both treatment modalities and were given the 
choice of treatment. 
The inpatients perceived many benefits for their treatment modality; feeling secure at the 
hospital especially in the lack of family support at home, avoiding long travel distances from 
home, fear from having a CAD. This treatment group complained from admission delays, 
long waiting times to receive treatment, and extension of hospital stay.  
The outpatient treatment group appreciated the reduced commuting times, improved 
quality of life, sense of independence, being home, and satisfactory nursing care at home. 
3/13 patients developed CAD related complications but were successfully treated and all 
patients were satisfied with their choice of treatment and expressed adhering to it for future 
sessions. 
The quality of life was measured using a validated tool; the European Organization for 
Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30). Outpatient 
treatment was associated with better quality of life and less cost compared to inpatient 
treatment. In light of these benefits, outpatient treatment became standard of care at the 
centre (59).  
A retrospective single centre study in Korea evaluated the patient satisfaction and cost of 
ambulatory versus inpatient chemotherapy treatment with FOLFOX in 80 patients having 
similar baseline characteristics.  
All patients were admitted to the hospital at least for their first cycle and then randomized 





treatments but with a slight variance in dosing. Inpatients received two 5FU infusions over 
22 hours while ambulatory patients received one pump with the adequate dose of 5FU to 
infuse over 2 days. 
Ambulatory treated patients expressed higher satisfaction than inpatients in terms of cost, 
level of discomfort, burden on family members, waiting time, worries about chemotherapy 
and understanding its schedule, and awareness of the potential side effects (p<0.05). 
Although inpatients had to worry less about their injection site and experienced a better 
management of nausea episodes, overall satisfaction was still higher in the outpatient group. 
Additionally, AC incurred significantly lower costs compared to inpatient treatment (3).  
In a comparative study conducted in China between inpatient (N=52) and ambulatory (N=50) 
treatment, three factors were found to influence patient’s choice of treatment; educational 
level, family responsibilities, and employment. Patients in the ambulatory treatment group 
were more educated, more likely to be employed and be the primary caregiver of the family. 
These findings comply with the primary advantage of ambulatory treatment that is patients 
not being restricted to their hospital beds and carrying out their normal daily activities while 
receiving treatment. It was interesting to note that although patients were happier to 
receive ambulatory therapy, they did experience more fatigue, nausea and vomiting than 
their counterparts. The authors highlighted the need for appropriate medical counselling on 
lifestyle modifications and use of rescue oral therapy for chemotherapy induced nausea and 
vomiting (7).  
AC using portable infusion pumps is gaining momentum in Hong Kong as three recent 
publications have described its impact on patients’ quality of life and decreases pressure on 
healthcare resources (57,58,60). This was following a successful delivery of 29 infusion to 24 
cancer patients between November 2017 and March 2019.  
7.0 Practice-based challenges with Ambulatory Chemotherapy and Research guided 
solutions 
The paucity of literature assessing the performance of EIP in clinical practice, encouraged 
researchers from Kingston University to conduct a two-phase audit between 2013 and 2014. 
The study aimed at evaluating the accuracy of EIP and patient satisfaction at three 
gastrointestinal units of the Royal Marsden hospitals through an observational study and a 
survey. 
The observational study collected data required to assess the infusion duration, remaining 
volume (if any) at disconnection time, action taken in case of incomplete pump emptying at 
the pre-set disconnection time. Additional variables that could possibly affect pump accuracy 





The survey assessed patients’ experience and satisfaction with the pump. 
5FU was mainly infused through CAD to patients aged 29-88 years. 
Forty percent of calculated infusion rates were slower than those labelled, and 57% of these 
pumps were discarded with considerable remnant volumes of 5FU. These findings impact 
not only treatment outcomes but also nurses’ workload and patient waiting times. 
Researchers were, however, unable to collect percentages of pumps infusing faster than 
labelled as patients came before their scheduled visit. 
Despite the high patient satisfaction scored, it is essential to mitigate the impact of pump 
accuracy on treatment outcomes (61). 
Consequently, a subgroup of these researchers collaborated with computer scientists from 
Kingston University to develop a software that uses digital images for assessing pump 
performance. By monitoring the remaining volumes in the pump, the software generates an 
estimate of the end of infusion time. Preliminary results were promising and could support 
detecting inconsistencies in treatment delivery early enough to avoid serious complications 
(62). 
Another group of Canadian researchers and clinicians assessed the feasibility of weighing the 
5FU pumps as an alternative to visual inspection when checking for residual volumes at 
disconnection (hour 46). Filled and empty pumps were weighed using a pharmacy and a 
kitchen scale. Weighing proved to be an acceptable estimate of the volume and time that 
have elapsed and are remaining for 5FU delivery even with a kitchen scale, readily accessible 
for patients. In addition to generating figures useful for these calculations, the study also 
proved that in many instances the remaining volume was greater than 10%, the renowned 
acceptable margin. This further highlights the importance of a practical tool for patients to 
monitor the rate of treatment delivery (63). 
The researchers built on these findings to conduct another study whereby patients were 
asked to present to the hospital midway through their treatment to check for the rate of 
infusion based on its weight. On average, the observed pumps had a flow rate (13.7%) 
greater than that labelled and its acceptable variability. However, estimated flow rates at 
each hour between 17 and 27 were lower than expected. This correlates with the 
declaration of the pump’s manufacturer that flow rates and not constant. This study 
reinforced the use of weight for monitoring drug delivery but not estimated end time of 
infusion due to the inherent variability of the flow rate (64). 
8.0 Conclusion 
Ambulatory chemotherapy is a feasible alternative to hospital stay based on patient and 





has been the focus of recent research using novel ways to mitigate them. At current times of 
Covid-19 pandemic, it is essential to ensure patient care continuum while maintaining safety 
and positive experience. With careful considerations and adequate infrastructure in place, 
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• Ambulatory chemotherapy uses portable infusion pumps to deliver chemotherapy at 
home 
• Positive experiences using ambulatory chemotherapy warrants its use at times of Covid-
19 pandemic 
• Recent research using technology and tools accessible for patient is addressing practice-
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Table 1 Innovations and developments in chemotherapy treatment 
Chemotherapy treatment Definition 
One-day hospital unit/Outpatient care Outpatient hospital unit reserved for patients 
requiring short intravenous infusions over few hours 
on a daily, weekly or monthly basis 3 
Mobile chemotherapy units (MCUs) These mobile units are driven to a specified location 
conveniently close to patients to deliver 
chemotherapy treatments beyond the second 
session. MCU are managed by the same staff 
operating in the outpatient care. In 2007, the first 
MCU was launched in the UK 4  
Home chemotherapy/hospital-at-
home care 
Administration of intravenous chemotherapy at home 
under direct medical supervision by a specialist nurse; 
suited for patients wanting to avoid admission to the 
outpatient care or oncology ward for infusions lasting 
hours to days 3 
Oral chemotherapy drugs Chemotherapy formulated as capsules and tablets 
currently available for many cancers 5 
Ambulatory chemotherapy Delivery of chemotherapy outside the hospital using a 
portable infusion pump connected to patients at the 
hospital. This modality enables patients to receive 
continuous infusions lasting up to 7 days while freely 
ambulating 6-8 
 
Table 2 Types of disposable mechanical pumps 
 Positive Pressure Negative Pressure Elastomeric  
Mode of 
action 
As the drug 
reservoir of the 
pump gets filled 
with the solution, 
it compresses the 
spring contained 
the vacuum or area 
of very low pressure 
in one chamber of 
the pump becomes 
aggravated as the 
opposite chamber 
A stretchable 
elastomer intended to 
hold the solution is 
contained within an 
outer protective shell 





within which in 
turn exerts 




through the tubing 
gets filled with the 
solution. The 
significant difference 
in pressure between 
the two chambers 
causes the movable 
wall plunger to push 
the fluid out through 
the tubing 
or a softer material. 
Once filled with the 
drug solution, the 
membranes of the 
elastomer exert 
pressure on the 
solution driving it out 






Entirely disposable Entirely disposable 
Accuracy +/- 10 to +/- 20 +/- 10% +/- 15% 
 
Table 1 Immediate and delayed complications of CAD 
Immediate Complications (Incidence) 















Injury to the recurrent laryngeal nerve 
Air embolus 
Delayed Complications 
Device dysfunction Fibrin sheath formation 
Fracture 
Thrombosis 





Table 2 Types, description and features of the three main types of Central Access Devices 
Types of CAD Description Features 
Tunnelled Catheter  Catheter inserted by tunnelling 
under the skin into the subclavian 
or internal jugular vein. The part 
used to administer or withdraw 
fluids remains outside the body 
(e.g. Hickman, Broviac) 
Serves for a long period 
and is adequate for 
administration of fluids 
such as chemotherapy, 
blood products and 
parenteral feeding. 





Line inserted into a large vein in 
the arm (hence the name 
peripheral) and advanced 
forward into the subclavian vein 
Could serve up to 12 
months, no needle 
sticks required, placed 
at bedside 
Associated with a 










Port placed completely below the 
skin consisting of a chamber 
component, raised disk of around 
1-inch diameter underneath the 
skin, and a connected thin flexible 
tube extending into a major vein. 
Access is ensured using a special 
needle, Huber needle, inserted 
into the chamber on one end, 
and connected to the syringe or 
infusion on the other end 
Long term patency 
while maintaining low 
infection risks 
 
